How GLP-1 Gut Peptide Drugs Became a Breakthrough for Treating Obesity | Research

The takeaway

This review explains how GLP-1 receptor agonists exploit the gut-brain peptide signaling axis to suppress appetite and promote weight loss, establishing them as a new drug class for obesity treatment.

New drug class for obesity
After decades with few effective obesity medications, GLP-1 receptor agonists targeting the gut-brain peptide axis emerged as a breakthrough, starting with liraglutide 3.0 mg's approval.

What the researchers found

GLP-1 receptor agonists target the gut-brain axis to regulate appetite and promote weight loss. Liraglutide 3.0 mg was approved for obesity treatment in adults with BMI ≥27 kg/m² and comorbidities. The review covers how GLP-1 — a peptide naturally produced in the gut — coordinates appetite regulation through brain signaling, and how pharmacological GLP-1 RAs amplify these effects to produce clinically meaningful weight loss. Other GLP-1 RAs were identified as promising future obesity treatments.

Why it matters

This review captures a pivotal moment in obesity medicine — the transition from having almost no effective pharmacological treatments to the emergence of GLP-1 receptor agonists as a viable drug class. By explaining how gut-derived peptides regulate the brain's appetite centers, it laid the groundwork for the GLP-1 drug revolution that has since transformed obesity treatment with drugs like semaglutide and tirzepatide.

The numbers in context

Liraglutide 3.0 mg approved dose · BMI ≥27 kg/m² with comorbidities · 30+ years of rising global obesity · review covers gut-brain axis peptide signaling · multiple GLP-1 RAs discussed

How the study worked

This is a narrative review summarizing the role of the gut-brain axis in appetite regulation, the biology of GLP-1 peptide signaling, the mechanism of action of GLP-1 receptor agonists for weight loss, and clinical trial data supporting their use in obesity management.

Who was studied

Review covering adults with overweight (BMI ≥27 with comorbidities) and obesity treated with GLP-1 receptor agonists

What this study cannot tell us

Published before the explosive growth of GLP-1 RA use for obesity, this review covers primarily liraglutide data. Semaglutide for obesity and tirzepatide were not yet approved or fully studied. Long-term outcome data and real-world effectiveness were limited at the time. The review does not address the now-recognized cardiovascular benefits of GLP-1 RAs.

How to read the evidence

This is a narrative review synthesizing clinical trial data and mechanistic research. The underlying evidence includes randomized controlled trials that led to regulatory approval, representing high-quality evidence, though the review format is qualitative.

When this study was published

Published in 2017, this review captures the early era of GLP-1 drugs for obesity. Since then, semaglutide 2.4 mg and tirzepatide have been approved with even greater weight loss efficacy, and the field has expanded dramatically.

The bigger picture

This 2017 review stands at the beginning of what has become the most transformative development in obesity medicine in history. The gut-brain peptide signaling framework it describes has been validated spectacularly — GLP-1 and dual GIP/GLP-1 drugs have become some of the most prescribed medications worldwide. The review's prediction that other GLP-1 RAs would offer promise for obesity has been fulfilled beyond anyone's expectations.

Questions still open

How do the newer obesity-dose GLP-1 RAs (semaglutide 2.4 mg) compare to liraglutide 3.0 mg in weight loss efficacy?
Can GLP-1 RA therapy be combined with other gut peptide-targeting drugs for even greater weight loss?
What happens to appetite regulation when patients discontinue GLP-1 RA therapy?

Common questions

How does GLP-1 control appetite?

When you eat, cells in your gut release the peptide GLP-1, which travels to the brain and activates areas that control hunger and fullness. GLP-1 also slows stomach emptying, so food stays in your stomach longer, and it helps regulate insulin release. GLP-1 drugs amplify these natural effects by providing much higher and longer-lasting levels of GLP-1 signaling than food alone can produce.

Why is liraglutide 3.0 mg different from the diabetes dose?

Liraglutide for diabetes is prescribed at 1.2-1.8 mg daily, which is enough to improve blood sugar control. For obesity treatment, a higher dose of 3.0 mg is needed because greater GLP-1 receptor activation is required to significantly suppress appetite and produce meaningful weight loss. This higher dose was specifically studied and approved for weight management.

Read the original research

Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.

Obesity reviews : an official journal of the International Association for the Study of Obesity, 18(1), 86-98

View on PubMed ↗Publisher’s paper ↗

Citation

Burcelin, R; Gourdy, P. (2017). Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 18(1), 86-98. https://doi.org/10.1111/obr.12465